Cargando…
Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma
SIMPLE SUMMARY: Glioblastomas are high-grade brain tumours and are the most common form of malignancy arising in the brain. Patient survival has improved little over the last 40 years, highlighting an urgent unmet need for more effective treatments for these tumours. Current standard-of-care treatme...
Autores principales: | Carmell, Natasha, Rominiyi, Ola, Myers, Katie N., McGarrity-Cottrell, Connor, Vanderlinden, Aurelie, Lad, Nikita, Perroux-David, Eva, El-Khamisy, Sherif F., Fernando, Malee, Finegan, Katherine G., Brown, Stephen, Collis, Spencer J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956595/ https://www.ncbi.nlm.nih.gov/pubmed/33668183 http://dx.doi.org/10.3390/cancers13050944 |
Ejemplares similares
-
Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients
por: Gagg, Hannah, et al.
Publicado: (2023) -
DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells
por: Vanderlinden, Aurelie, et al.
Publicado: (2023) -
Tumour treating fields therapy for glioblastoma: current advances and future directions
por: Rominiyi, Ola, et al.
Publicado: (2020) -
Correction: Tumour treating fields therapy for glioblastoma: current advances and future directions
por: Rominiyi, Ola, et al.
Publicado: (2021) -
DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies
por: Rominiyi, Ola, et al.
Publicado: (2021)